Alternative Care in Patients With Auto-Immune Diseases
Alter-MAI
Proportion of the Use of Medicines and Alternative Care in Patients With Auto-Immune Diseases Alter-MAI
1 other identifier
observational
121
1 country
1
Brief Summary
Patients followed in Internal Medicine bring together favorable conditions for the use of alternative medicines. While some are recognized for their benefits, some can, on the contrary, harm the patient. It is therefore proposed to make a complete descriptive inventory of these practices, through an anonymized questionnaire. The main objective is the evaluation of the proportion of the use of alternative medicines in patients with in the department of Internal Medicine A
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 9, 2019
CompletedFirst Submitted
Initial submission to the registry
September 16, 2019
CompletedFirst Posted
Study publicly available on registry
September 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedMarch 27, 2026
August 1, 2022
2.2 years
September 16, 2019
March 24, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
The number of patients using alternative medicine.
Counting the number of patients using alternative medicine.
At day 1
Interventions
patients will respond to a specific questionnaire regarding the use of alternative medicine
Eligibility Criteria
Patient with systemic lupus erythematosus (ARA and/or SLICC criteria) OR with primary Sjögren's syndrome (revised Americano European criteria) OR with systemic scleroderma (ACR/EULAR 2012 criteria)
You may qualify if:
- Patient with systemic lupus erythematosus (ARA and/or SLICC criteria) OR with primary Sjögren's syndrome (revised Americano European criteria) OR with systemic scleroderma (ACR/EULAR 2012 criteria)
- Patient with signed consent
You may not qualify if:
- Patients deprived of their liberty
- Minors and adults subject to legal protection measures
- Patients subject to a justice safeguard measure
- Patient unable to understand or adhere to the protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Médecin Interne A
Limoges, France
Related Publications (1)
Couillard F, Parreau S, Dumonteil S, Ratti N, Palat S, Bezanahary H, Liozon E, Ly KH, Fauchais AL, Gondran G. Use of Complementary and Alternative Medicine by Patients Treated for Systemic Lupus Erythematosus, Primary Sjogren's Syndrome, or Systemic Sclerosis in a French Rural Region. Complement Med Res. 2024;31(3):234-240. doi: 10.1159/000536580. Epub 2024 Feb 12.
PMID: 38346411RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 16, 2019
First Posted
September 18, 2019
Study Start
September 9, 2019
Primary Completion
December 1, 2021
Study Completion
December 1, 2021
Last Updated
March 27, 2026
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will not share